RETA PEN

Retatrutide is an investigational injectable medication being developed by Eli Lilly as a potential treatment for obesity and type 2 diabetes. It belongs to a novel class of drugs known as triple receptor agonists, distinguishing it from earlier-generation weight-loss medications. Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors:

• GLP-1 (glucagon-like peptide-1) receptor – which reduces appetite and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptor – which enhances insulin secretion and may improve fat metabolism

• Glucagon receptor – which may increase energy expenditure and, based on early clinical and preclinical data, could promote hepatic fat metabolism

This triple-action mechanism sets Retatrutide apart from existing approved therapies such as Semaglutide (a GLP-1 agonist) or Tirzepatide (a dual GLP-1/GIP agonist). By engaging all three pathways simultaneously, Retatrutide is designed to produce a more pronounced effect on body weight and metabolic health than single or dual agonists, though direct head-to-head comparative trials have not yet been conducted.